Evaluation of Insulin and Glucagon-Like Peptide-1 Analog Sales in Turkey Before the Pandemic Period; Projection for Upcoming Years: A Market Analysis Study Pandemi Dönemi Öncesinde Türkiye’de İnsülin ve Glukagon Benzeri Peptid-1 Analog Satışlarının Değerlendirilmesi; Önümüzdeki Yıllar İçin Projeksiyon: Bir Pazar Analiz Çalışması
Sakarya Medical Journal, cilt.13, sa.1, ss.48-54, 2023 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 13 Sayı: 1
- Basım Tarihi: 2023
- Doi Numarası: 10.31832/smj.1021311
- Dergi Adı: Sakarya Medical Journal
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.48-54
- Anahtar Kelimeler: Diabetes mellitus, Glucagon-like peptide-1 analog sales, Insulin sales
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Introduction Materials and Methods Results Conclusion This study was designed to evaluate the box sale trends of insulin preparations and glucagon-like peptide-1 (Glp-1) analogs by their therapeutic categories in Turkey. Also, we aimed to project sale trends of these pharmaceuticals in next years. We analyzed the data before the covid-19 pandemic and made predictions based on these data. This study analyzed retail and hospital box sales of insulin preparations from 4 therapeutic categories (fast/short-acting, intermediate-acting, premix, long-acting) and Glp-1 analogs. Total box sales of the insulin preparations were increased by %13,30 in the period examined. While fast/short-acting and long-acting insulin box sales increased with a decreasing upward trend, intermediate-acting and premix insulin box sales decreased. Glp-1 analog sales increased rapidly in this period. Currently, newer pharmaceuticals have been entering Turkish market for diabetes treatment. Less insulin might be required if newer pharmaceuticals are more widely available in diabetes treatment. Also it will be useful to evaluate the effect of the pandemic on access to pharmaceuticals used in the treatment of chronic diseases in future studies.